Amedisys’ (AMED) Outperform Rating Reaffirmed at Royal Bank of Canada

Amedisys (NASDAQ:AMED)‘s stock had its “outperform” rating reissued by equities research analysts at Royal Bank of Canada in a note issued to investors on Wednesday,Benzinga reports. They currently have a $100.00 price objective on the health services provider’s stock. Royal Bank of Canada’s price target would suggest a potential upside of 8.98% from the stock’s current price.

Separately, Stephens restated an “equal weight” rating and set a $101.00 price objective on shares of Amedisys in a report on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $100.75.

Amedisys Price Performance

Amedisys stock opened at $91.76 on Wednesday. Amedisys has a 12-month low of $82.15 and a 12-month high of $98.95. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. The firm has a 50-day moving average price of $92.16 and a 200-day moving average price of $91.94. The firm has a market capitalization of $3.01 billion, a PE ratio of 36.41, a price-to-earnings-growth ratio of 1.78 and a beta of 0.89.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings data on Wednesday, February 26th. The health services provider reported $0.96 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.05 by ($0.09). Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The firm had revenue of $598.05 million during the quarter, compared to the consensus estimate of $602.38 million. As a group, equities research analysts forecast that Amedisys will post 4.4 EPS for the current year.

Institutional Trading of Amedisys

Several institutional investors and hedge funds have recently modified their holdings of AMED. MassMutual Private Wealth & Trust FSB grew its stake in Amedisys by 56.1% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 334 shares of the health services provider’s stock worth $31,000 after purchasing an additional 120 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of Amedisys by 55.1% in the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock worth $34,000 after buying an additional 124 shares during the period. Fifth Third Bancorp grew its position in shares of Amedisys by 68.1% during the 1st quarter. Fifth Third Bancorp now owns 348 shares of the health services provider’s stock worth $32,000 after buying an additional 141 shares in the last quarter. Xponance Inc. increased its stake in shares of Amedisys by 3.5% during the fourth quarter. Xponance Inc. now owns 4,349 shares of the health services provider’s stock valued at $395,000 after buying an additional 148 shares during the period. Finally, Inspire Investing LLC raised its holdings in shares of Amedisys by 3.6% in the fourth quarter. Inspire Investing LLC now owns 4,405 shares of the health services provider’s stock valued at $400,000 after acquiring an additional 155 shares in the last quarter. Institutional investors own 94.36% of the company’s stock.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.